Russell Investments Group Ltd. Has $13.30 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Russell Investments Group Ltd. reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 359,706 shares of the biopharmaceutical company's stock after selling 62,986 shares during the period. Russell Investments Group Ltd. owned approximately 0.27% of Halozyme Therapeutics worth $13,295,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HALO. Commonwealth Equity Services LLC lifted its stake in shares of Halozyme Therapeutics by 2.2% in the third quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company's stock valued at $619,000 after buying an additional 347 shares during the period. Washington Capital Management Inc. bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $592,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Halozyme Therapeutics by 2.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 75,798 shares of the biopharmaceutical company's stock worth $2,895,000 after purchasing an additional 2,139 shares in the last quarter. Park Avenue Securities LLC bought a new stake in shares of Halozyme Therapeutics during the third quarter valued at approximately $293,000. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Halozyme Therapeutics by 174.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company's stock valued at $33,894,000 after purchasing an additional 563,989 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

HALO stock traded up $0.09 during midday trading on Friday, reaching $39.91. 902,802 shares of the company's stock traded hands, compared to its average volume of 866,867. The company has a 50-day simple moving average of $39.99 and a two-hundred day simple moving average of $37.91. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics, Inc. has a 1-year low of $29.85 and a 1-year high of $45.00. The company has a market cap of $5.07 billion, a price-to-earnings ratio of 18.91, a PEG ratio of 0.47 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts' consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total value of $384,900.00. Following the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at approximately $6,473,094.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have sold 30,000 shares of company stock worth $1,196,800. Corporate insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of several analyst reports. StockNews.com raised shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, February 23rd. JMP Securities reissued a "market outperform" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, April 30th. Benchmark reissued a "buy" rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. Finally, The Goldman Sachs Group cut their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a "neutral" rating for the company in a research report on Thursday, January 18th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of "Moderate Buy" and an average target price of $53.29.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.